Phase 1 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have signed a written consent form agreeing to take part in the study
- Adults aged 18 or older
- People who have been diagnosed with a specific type of brain tumour called glioblastoma (IDH-wildtype, as classified by WHO 2021 guidelines) that has come back after previous radiation treatment — and if the tumour has a certain genetic marker (MGMT promoter methylation), at least 12 weeks must have passed since radiation treatment ended
- People whose tumour tissue has tested positive for a specific gene change called "wild-type EGFR amplification," tested by a specific laboratory (NeoGenomics Laboratories), using either stored tissue from the original diagnosis or newly collected tissue
- People for whom the treating doctor considers surgery to remove or reduce the tumour, or a biopsy to confirm the tumour has returned, to be medically appropriate
- People whose kidneys, liver, and heart are functioning at an adequate level, as determined by specific blood and heart tests (confirm specific thresholds with trial site)
- People whose lungs are functioning adequately, with no more than mild breathlessness and blood oxygen levels above 92% while breathing normal room air
- People with a Karnofsky Performance Status score of 60% or higher — a medical measure of a person's ability to carry out daily activities (confirm with trial site)
- People who are able to have children and who agree to use acceptable contraception methods as outlined in the trial protocol
Who may not be able to join:
- People with an active hepatitis B or hepatitis C infection
- People with any other active infection that is not under control
- People with a serious heart condition classified as Class III or IV under a standard medical rating system (confirm with trial site)
- People whose tumour is located mainly in the brain stem or spinal cord
- People with serious other health conditions that, in the treating doctor's opinion, would make participation unsafe
- People who have received a drug called bevacizumab within the 3 months before the treating doctor confirms eligibility for the trial
- People with an active autoimmune disease that requires ongoing immune-suppressing medication at a certain dose level, or people with autoimmune neurological conditions such as multiple sclerosis or Parkinson's disease
- People who are currently pregnant or breastfeeding
- People with a known allergy or sensitivity to any of the ingredients in the study treatment, including human serum albumin, DMSO, or Dextran 40
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Stephen Bagley, MD, MSCE, University of Pennsylvania
Phone: 215-349-8245
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Subjects with treatment related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCAE) V5.0; Occurrence of treatment-limiting toxicities (Arms A and B only)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.